Cantor Fitzgerald analyst Jennifer Kim upgraded ProQR Therapeutics (PRQR) to Overweight from Neutral with a price target of $5.00, up from 80c, after the company announced an expansion of its collaboration and licensing agreement with Eli Lilly (LLY) focused on the discovery, development and commercialization of new genetic medicines. The partnership expansion provides validation, and the analyst has "warmed up" to ProQR ahead of what she believes could be a big year for the company in 2023, Kim tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PRQR:
- PRQR Skyrockets Following Expanded Collaboration with LLY
- ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform
- Lilly and ProQR to Expand RNA Editing Collaboration
- Eli Lilly, ProQR expand genetic medicines licensing and collaboration agreement
- Eli Lilly, ProQR Therapeutics to expand RNA editing collaboration
